Valuation: Whitehawk Therapeutics, Inc.

Market Cap 232M 201M 190M 172M 323M 22.26B 325M 2.27B 873M 11.29B 872M 852M 35.99B P/E 2026 *
-4.46x
P/E 2027 * -4.63x
Enterprise Value 232M 201M 190M 172M 323M 22.26B 325M 2.27B 873M 11.29B 872M 852M 35.99B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.37%
Yield 2026 *
-
Yield 2027 * -
1 day+0.49%
1 week-11.09%
Current month-9.91%
1 month-8.30%
3 months-1.68%
6 months+4.60%
Current year+69.01%
1 week 3.96
Extreme 3.96
4.49
1 month 3.96
Extreme 3.96
5.1
Current year 2.36
Extreme 2.36
5.5
1 year 1.8
Extreme 1.805
5.5
3 years 1.21
Extreme 1.21
5.7
5 years 1.21
Extreme 1.21
32.99
10 years 1.21
Extreme 1.21
32.99
Manager TitleAgeSince
Chief Executive Officer 55 2023-10-01
Chief Executive Officer 55 2023-03-02
Chief Tech/Sci/R&D Officer 69 2025-11-30
Director TitleAgeSince
Chairman 61 2022-12-31
Chairman 55 2017-02-28
Director/Board Member 54 2021-08-25
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 Free

Director

76,080 0.1614%
5/14/26 Free

Chairman

255,102 0.5413%
5/14/26 Free

Chief Technology Officer

19,132 0.0406%
Change 5-day change 1-year change 3-year change Capi.($)
+0.49%-11.09%+105.53%-31.03% 232M
-2.47%-6.48%+38.23%-7.00% 79.26B
-1.99%-1.22%+511.53%+27.44% 58.56B
+1.57%+0.62%-16.15%-34.72% 58.62B
-0.56%-3.68%-11.53%+25.63% 48.75B
-0.29%-0.19%+1.21%+154.61% 46.32B
-0.55%-2.11%+49.23%-15.66% 32.12B
-0.37%-3.95%+46.50%+91.78% 24.77B
-1.91%-6.22%-2.91%+151.66% 21.5B
-1.92%-2.31%+62.94%+96.25% 15.97B
Average -0.80%-2.88%+78.46%+45.90% 38.61B
Weighted average by Cap. -0.94%-1.85%+91.26%+36.23%

Financials

2026 *2027 *
Net sales - -
Net income -74.98M -64.95M -61.42M -55.6M -104M -7.19B -105M -733M -282M -3.65B -282M -275M -11.63B -85.12M -73.74M -69.72M -63.12M -118M -8.17B -119M -832M -320M -4.14B -320M -313M -13.2B
Net Debt - -
Logo Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Employees
32
Date Price Change Volume
26-09-15 US$4.090 +0.49% 142,334
26-09-14 US$4.070 -0.97% 166,030
26-09-11 US$4.110 +0.98% 283,519
26-09-10 US$4.070 -2.86% 1,291,640
26-09-09 US$4.190 -4.56% 168,324
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.070USD
Average target price
7.500USD
Spread / Average Target
+84.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. WHWK Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!